Deal Watch: Alexion Encouraged By RNAi Developments, Partners With Dicerna

 
• By Joseph Haas, Brian Yang, Jo Shorthouse, and Jung Won Shin

Alexion thinks Dicerna’s RNAi technology could address complement-mediated conditions further upstream from antibodies like Soliris. AbbVie takes over CF collaboration with Galapagos, paying $45m up front.

DealWatch_1200x675

More from Deals

More from Business